Panacea Index Logo

Command Palette

Search for a command to run...

Propensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF.

Scientific reports
January 14, 2025
Lijun Song et al. (5 authors)
Journal ArticleHuman Study
Study Details

Study Goal

The researchers aimed to determine whether magnesium supplementation reduces mortality rates in patients with heart failure with preserved ejection fraction (HFpEF).

Results Summary

Magnesium supplementation significantly reduced 28-day all-cause mortality, particularly in older patients, females, and those with hypertension or without diabetes. However, it also led to longer ICU and hospital stays.

Population

HFpEF patients from the MIMIC-IV database (2008-2019), with 985 patients in each group after propensity score matching.

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (10)
InterventionDirectionEndpointPopulationDosageImpactClaim #
magnesium supplementation (including magnesium sulfate and magnesium oxide)
decrease
28-day all-cause mortality rate
HFpEF patients
hazard ratio [HR], 0.682; 95% confidence interval [CI], 0.539-0.863
significantly contributed to a decrease
#1
magnesium supplementation (including magnesium sulfate and magnesium oxide)
decrease
28-day all-cause mortality rate
older patients
HR, 0.65; 95% CI 0.52-0.81
significantly contributed to a decrease
#2
magnesium supplementation (including magnesium sulfate and magnesium oxide)
decrease
28-day all-cause mortality rate
females
HR, 0.55; 95% CI 0.41-0.73
significantly contributed to a decrease
#3
magnesium supplementation (including magnesium sulfate and magnesium oxide)
decrease
28-day all-cause mortality rate
those with hypertension
HR, 0.62; 95% CI 0.48-0.79
significantly contributed to a decrease
#4
magnesium supplementation (including magnesium sulfate and magnesium oxide)
decrease
28-day all-cause mortality rate
those without diabetes
HR, 0.54; 95% CI 0.41-0.71
significantly contributed to a decrease
#5
magnesium treatment
decrease
ICU mortality rates
HFpEF patients
-
improved
#6
magnesium treatment
decrease
one-year mortality rates
HFpEF patients
-
improved
#7
magnesium treatment
increase
ICU stays
HFpEF patients
-
resulted in extended
#8
magnesium treatment
increase
hospital stays
HFpEF patients
-
resulted in extended
#9
magnesium intake
neutral
mortality
HFpEF patients
approximately 22.73%
mediated by
#10
Abstract

Heart failure with preserved ejection fraction (HFpEF) emerges as a singular subclass of heart failure, bereft of specific therapeutic options. Magnesium, an indispensable trace element, is essential to the preservation of cardiac integrity. However, the association between magnesium supplementation and mortality in HFpEF patients remains unclear. This study extracted HFpEF patient data from the MIMIC-IV database between 2008 and 2019. Propensity score matching was conducted to ensure that patients receiving magnesium supplementation (including magnesium sulfate and magnesium oxide) were balanced with those not receiving it in terms of baseline characteristics. The primary analysis focused on the 28-day all-cause mortality rate, with secondary endpoints encompassing ICU and one-year mortality rates, along with the duration of hospitalization. After matching, the study's final cohort balanced at 1970 patients, with 985 patients per group. The results showed that magnesium intake significantly contributed to a decrease in the 28-day all-cause mortality rate (hazard ratio [HR], 0.682; 95% confidence interval [CI], 0.539-0.863), particularly in subgroups such as older patients (HR, 0.65; 95% CI 0.52-0.81), females (HR, 0.55; 95% CI 0.41-0.73), and those with hypertension (HR, 0.62; 95% CI 0.48-0.79) or without diabetes (HR, 0.54; 95% CI 0.41-0.71). Although magnesium treatment improved both ICU and one-year mortality rates, it concurrently resulted in extended ICU and hospital stays. Mediation analysis indicated that blood urea nitrogen partially mediated the association between magnesium intake and mortality, accounting for approximately 22.73% of the observed effect. Magnesium supplementation has illustrated a significant potential for mitigating the mortality rate in the HFpEF patient, particularly among the elderly, female, and individuals with hypertension. Therefore, magnesium supplementation stands as a potentially valuable supplementary treatment modality for patients with HFpEF. Further comprehensive research is warranted to explore its effects more deeply.

Medical Subject Headings (MeSH)
HumansFemaleMaleAgedPropensity ScoreDietary SupplementsMagnesiumHeart FailureCritical IllnessStroke VolumeAged, 80 and overMiddle AgedCohort Studies
Study Links
Quality Scores
SafetyNot Assessed
Efficacy85/10
Quality78/10
Research Impact Scores
APT Score0.05
Weight Score2.56
Normalized Score0.70
Related Supplements
Propensity score matched cohort study on magnesium supplemen... | Panacea Index